Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2016 - 2018)

Ironwood Pharmaceuticals (IRWD) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $6.3 million as the latest value for Q4 2018.

  • Quarterly Non-Current Deffered Revenue rose 15.76% to $6.3 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2018, up 15.76% year-over-year, with the annual reading at $6.3 million for FY2018, 15.76% up from the prior year.
  • Non-Current Deffered Revenue hit $6.3 million in Q4 2018 for Ironwood Pharmaceuticals, up from $6.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $10.1 million in Q1 2014 to a low of $557000.0 in Q4 2016.
  • Historically, Non-Current Deffered Revenue has averaged $5.7 million across 5 years, with a median of $6.0 million in 2018.
  • Biggest five-year swings in Non-Current Deffered Revenue: plummeted 80.0% in 2015 and later soared 878.28% in 2017.
  • Year by year, Non-Current Deffered Revenue stood at $9.0 million in 2014, then tumbled by 80.0% to $1.8 million in 2015, then crashed by 69.02% to $557000.0 in 2016, then skyrocketed by 878.28% to $5.4 million in 2017, then increased by 15.76% to $6.3 million in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for IRWD at $6.3 million in Q4 2018, $6.1 million in Q3 2018, and $6.1 million in Q2 2018.